• Patient and Prescribing Information
ParaPRO
  • Disease Focus
    • Head Lice
    • Scabies
  • Lead Compound
  • Product Overview
  • About Us
    • Leadership
    • Careers
  • Contact
Select Page

Sitemap

Pages

  • About Us
  • Careers
  • Contact
  • Disease Focus
    • Head Lice
    • Scabies
  • Home
  • How to End Super Lice in Cincinnati
  • How to End Super Lice in Cincinnati
  • How to End Super Lice in Dallas
  • How to End Super Lice in Dallas
  • How to End Super Lice in Nashville
  • How to End Super Lice in Nashville
  • Lead Compound
  • Management
  • Privacy Policy
  • Product Overview
  • Sitemap
  • Terms of Use
  • Sitemap
  • Privacy Policy
  • Terms of Use
© 2025 ParaPRO, LLC. All rights reserved.
Important Safety Information

Indication
Natroba™ Topical Suspension is a pediculicide indicated for the topical treatment of head lice infestations in patients six (6) months of age and older.

Adjunctive Measures
Natroba™ Topical Suspension should be used in the context of an overall lice management program:

Important Safety Information

Indication
Natroba™ Topical Suspension is a pediculicide indicated for the topical treatment of head lice infestations in patients six (6) months of age and older.

Adjunctive Measures
Natroba™ Topical Suspension should be used in the context of an overall lice management program:
• Wash (in hot water) or dry clean all recently worn clothing, hats, used bedding and towels
• Wash personal care items such as combs, brushes, and hair clips in hot water
• A fine-toothed comb or special nit comb may be used to remove dead lice and nits.

Important Safety Information
Natroba™ Topical Suspension contains benzyl alcohol and is not recommended for use in neonates and infants below the age of 6 months. Systemic exposure to benzyl alcohol has been associated with serious adverse reactions and death in neonates and low birth-weight infants when administered intravenously. Most common adverse events were: application site redness (3%), eye redness (2%) and application site irritation (1%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.